Document text
Principal Investigator: GEORGIA Doris TOMARAS
Organization: DUKE UNIVERSITY
Fiscal Year: 2024
Award: $4,307,324
Funding agency: National Institute of Allergy and Infectious Diseases
ABSTRACT_Overall
Preventing HIV-1 acquisition and extinguishing virus replication is a key goal for vaccine and
immunoprophylaxis strategies. Diverse antibody (Ab) Fc receptor (FcR)-mediated functions and multiple
effector cell populations engage in vivo in a joint merger to thwart infection. An improved understanding of
specific functional and qualitative features of the humoral response and how they contribute to protective
efficacy is needed. Results from immune correlates analyses of vaccine efficacy trials, immunoprophylaxis
trials and preclinical studies indicate that antibody constant (Fc) region mediated antiviral activity is an
untapped source of antiviral functions to afford broad and potent protection against HIV infection. Full
exploitation of this potential demands a more complete understanding of Fc-mediated immune mechanisms in
humans and animal models. Rational design of prevention methods requires more information regarding
epitope targets, cognate polyclonal antibody (Ab) isotypes and subclasses, diverse FcR and effector cell
populations, and most important, how these elements can be pulled together for the greatest antiviral impact.
The goal of this program is to define how Fc-mediated immunity can be used for preventing, treating,
curing HIV infection. We propose to determine the combined impact of antibody Fc and effector cells on
antiviral outcomes in situ, thus informing how antibody Fc effector functions can be used to improve antibody-
based vaccine strategies, increase the relative antiviral activity of HIV-1 specific antibody subclasses, and
augment bnAb- based prophylactic and therapeutic approaches. Our central hypothesis is that antibody
antiviral potency is maximal when multiple antibody specificities and subclasses are combined and that their
antiviral functions are modulated by the in vivo localization of FcR-bearing effector cells and host genetic
determinants of Fc-FcR engagement. Harnessing Fc function will improve bnAb vaccine strategies given the
need to increase the antiviral functions of neutralizing antibodies (nAbs) at sub-efficacious levels. Toward this
end, we propose three synergistic, inter-related Projects supported by two Cores and an Administrative Core to
achieve the following Overall Aims:
1. Identify combinations of bnAb and nnAb antibody specificities with maximal antiviral activity.
2. Define the contribution of antibody Fc domain (subclass, allotype) on antiviral functions.
3. Determine FcR and effector cell populations responsible for maximal Ab Fc antiviral functions in
situ.
Terms: <AIDS><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Allotypic Antibodies><Animal Model><Animal Models and Related Studies><Antibodies><Antibody Specificity><Antigenic Determinants><Autologous><Binding Determinants><Biologic Models><Biological Models><Biophysics><Blood Serum><COVID-19><CV-19><Cell Body><Cells><Cellular biology><Clinical><Clinical Research><Clinical Study><Clinical Treatment Moab><Collaborations><Communicable Diseases><Coronavirus Infectious Disease 2019><Educational process of instructing><Effector Cell><Elements><Environment><Epitopes><Fc Receptor><Fc domain><Genetic Determinism><Genotype><Goals><HIV Infections><HIV-1><HIV-I><HIV1><HTLV-III Infections><HTLV-III-LAV Infections><Heterogeneity><History><Human><Human Immunodeficiency Virus Type 1><Human T-Lymphotropic Virus Type III Infections><Human immunodeficiency virus 1><Immune><Immune response><Immune system><Immunes><Immunity><Immunoglobulin Allotypes><Immunological response><In Situ><In Vitro><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Joints><Knowledge><Learning><M mulatta><M. mulatta><Macaca mulatta><Mediating><Methods><Model System><Modeling><Modern Man><Monoclonal Antibodies><Outcome><Phagocytes><Phagocytic Cell><Population><Position><Positioning Attribute><Pre-Clinical Model><Preclinical Models><Prevention><Productivity><Property><Public Health><Receptor Cell><Recording of previous events><Research Resources><Research Specimen><Resources><Rhesus Macaque><Rhesus Monkey><Role><Sampling><Serum><Source><Specimen><Structure><Teaching><Testing><Therapeutic><Vaccines><Viral><Viral Activity><Viral Antibodies><Viral Function><Viral Physiology><Virus><Virus Replication><Work><amebocyte><anti-viral antibody><anti-viral immunity><antibody receptor><antiviral immunity><biophysical foundation><biophysical principles><biophysical sciences><cell biology><cohort><coronavirus disease 2019><coronavirus disease-19><coronavirus infectious disease-19><defined contribution><efficacy trial><emergent pandemic><emerging pandemic><experiment><experimental research><experimental study><experiments><fighting><genetic determinant><global health><histories><host response><human model><humanized mice><humanized mouse><immune system response><immunoprophylaxis><immunoresponse><improved><in vivo><mAbs><model of animal><model of human><monoclonal Abs><mouse model><murine model><neutralizing antibody><new pandemic><novel pandemic><pandemic><pandemic disease><pathogen><polyclonal antibody><pre-clinical study><preclinical study><prevent><preventing><programs><prophylactic><protective efficacy><rational design><response><social role><treatment planning><vaccine efficacy><vaccine strategy><viral multiplication><viral replication><virus multiplication>